Glaxo to double China R&D staff in few years
SHANGHAI (Reuters) - GlaxoSmithKline, the world's second-largest drugmaker, plans to double its research and development staff in China to 350 people in the next few years, an executive said on Tuesday.

 

More

  • Reliance Power a long term call: Chakraborty

    Amitabh Chakraborty, President Equity at Religare Securities feels that Reliance Power is a stock that is to be held for a longer period of time purely to play the power sector and the up side in the power sectors in India.

  • UNICORP INC /NEW (form S-1)

    UNICORP INC /NEW Files SEC form S-1, Securities Registration Statement